neo-pv-01
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02897765)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- neo-pv-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03597282 | Phase 1 | Aug 31, 2018 | Apexigen, Inc., Neon Therapeutics |
| NCT03380871 | Phase 1 | May 4, 2018 | Merck, Neon Therapeutics |
| NCT02897765 | Phase 1 | Oct 1, 2016 | Bristol-Myers Squibb, Neon Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neon Therapeutics | For profit | 3 | 3 | 1 | 2016 |
| Apexigen, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2016 |
| Merck | For profit | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1